Key result
GRK2 inhibition protects against adverse cardiac remodeling and dysfunction in preclinical heart failure models.
Answers are grounded in this paper and cite their sources.
INTRODUCTION: G protein-coupled receptor (GPCR) kinase-2 (GRK2) is a regulator of GPCRs, in particular β-adrenergic receptors (ARs), and as demonstrated by decades of investigation, it has a pivotal role in the development and progression of cardiovascular disease, like heart failure (HF). Indeed elevated levels and activity of this kinase are able to promote the dysfunction of both cardiac and adrenal α- and β-ARs and to dysregulate other protective signaling pathway, such as sphingosine 1-phospate and insulin. Moreover, recent discoveries suggest that GRK2 can signal independently from GPCRs, in a 'non-canonical' manner, via interaction with non-GPCR molecule or via its mitochondrial localization. Areas covered: Based on this premise, GRK2 inhibition or its genetic deletion has been tested in several disparate animal models of cardiovascular disease, showing to protect the heart from adverse remodeling and dysfunction. Expert opinion: HF is one of the leading cause of death worldwide with enormous health care costs. For this reason, the identification of new therapeutic targets like GRK2 and strategies such as its inhibition represents a new hope in the fight against HF development and progression. Herein, we will update the readers about the 'state-of-art' of GRK2 inhibition as a potent therapeutic strategy in HF.
No takes yet. Share an insight, caveat, or question.
Cannavò et al. (2017) conducted a review in Heart failure. GRK2 inhibition or genetic deletion was evaluated. GRK2 inhibition or genetic deletion protects the heart from adverse remodeling and dysfunction across preclinical animal models of heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: